Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

BACKGROUND: This trial aimed to analyse the safety, effectiveness and transcriptomic characteristics of neoadjuvant toripalimab plus chemotherapy in II–III non-small-cell lung cancer (NSCLC). METHODS: Patient eligibility mainly involved treatment-naive, clinical stage II–III and wild-type EGFR/ALK N...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xinsheng, Sun, Liangdong, Song, Nan, He, Wenxin, Xie, Boxiong, Hu, Junjie, Zhang, Jing, Yang, Jie, Dai, Jie, Bian, Dongliang, Xia, Haoran, Sun, Fenghuan, Xiong, Anwen, Luo, Jie, Zhang, Lele, Yu, Huansha, Liu, Ming, Liu, Hongcheng, Wang, Haifeng, Zhang, Haiping, Chen, Chang, Wu, Chunyan, Duan, Liang, Zhu, Yuming, Zhang, Peng, Jiang, Gening
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801594/
https://www.ncbi.nlm.nih.gov/pubmed/36581917
http://dx.doi.org/10.1186/s12916-022-02696-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801594/
https://www.ncbi.nlm.nih.gov/pubmed/36581917
http://dx.doi.org/10.1186/s12916-022-02696-4

Ejemplares similares